Dynavax exercises Symphony option for cash to fund Heplisav
This article was originally published in Scrip
Executive Summary
Dynavax Technologies is exercising its option to purchase Symphony Dynamo (SDI), reaping $20 million in cash and rights to hepatitis C and cancer therapy programmes that were licensed from Dynavax.